How does my body mass index (BMI) determine eligibility for Semaglutide or Tirzepatide?
Body mass index (BMI) is a number calculated from a person's weight and height. It is used to classify weight status and is a key factor in deciding if certain weight loss medications, like semaglutide and tirzepatide, are appropriate.
Eligibility Criteria Based on BMI
- Semaglutide and tirzepatide are FDA-approved for weight management in adults who meet one of the following BMI criteria:
- BMI of 30 or higher: This is considered the threshold for obesity. Adults with a BMI of 30 kg/m² or greater are eligible for these medications, even if they do not have other health problems related to weight.[1][2][3][4][5][6][7][8]
- BMI of 27 or higher with at least one weight-related health condition: Adults with a BMI between 27 and 29.9 kg/m² (classified as overweight) may be eligible if they also have at least one weight-related comorbidity. Common qualifying conditions include high blood pressure (hypertension), high cholesterol (dyslipidemia), type 2 diabetes, obstructive sleep apnea, or cardiovascular disease.[1][2][3][4][5][6][7][8]
Why is BMI Used?
BMI is a simple and widely used measure to estimate body fat and assess health risks related to weight. Clinical trials and guidelines use BMI to identify people who are most likely to benefit from weight loss medications and to ensure safe and effective use.[1][2][3][4][5][6][7][8]
Other Important Considerations
- Lifestyle Changes: These medications are meant to be used along with healthy eating and increased physical activity. They are not a substitute for lifestyle changes.[1][6][4]
- Comorbidities: If a person has a BMI of 27 or higher and a weight-related health problem, this increases the potential benefit of medication and is part of the eligibility criteria.[1][2][3][4][5][6][7][8]
- Age: Semaglutide is approved for adults and youth aged 12 and older, while tirzepatide is approved for adults aged 18 and older.[1]
- Contraindications: These medications are not suitable for everyone. People with a personal or family history of certain rare cancers (like medullary thyroid carcinoma) or specific genetic syndromes (like multiple endocrine neoplasia type 2) should not use them.[2]
Summary Table
BMI Range (kg/m²) | Additional Requirement | Eligible for Semaglutide/Tirzepatide? | References |
≥30 | None | Yes | |
27–29.9 | At least one weight-related health condition | Yes | |
<27 | Not eligible | No |
How to Calculate BMI
BMI is calculated as:
BMI = weight (kg) ÷ [height (m)]²
For example, a person who weighs 90 kg and is 1.7 meters tall has a BMI of 31.1.
Key Takeaways
- A BMI of 30 or higher, or a BMI of 27 or higher with a weight-related health problem, is required for eligibility for semaglutide or tirzepatide for weight management.
- These medications should be used together with healthy lifestyle changes.
- Always discuss with a healthcare provider to determine if these medications are appropriate, considering individual health history and goals.
References
Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society. Mozaffarian D, Agarwal M, Aggarwal M, et al. The American Journal of Clinical Nutrition. 2025;122(1):344-367. doi:10.1016/j.ajcnut.2025.04.023.
2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on Medical Weight Management for Optimization of Cardiovascular Health: A Report of the American College of Cardiology Solution Set Oversight Committee. Gilbert O, Gulati M, Gluckman TJ, et al. Journal of the American College of Cardiology. 2025;:S0735-1097(25)06504-0. doi:10.1016/j.jacc.2025.05.024.
8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes-2025. Diabetes Care. 2025;48(Supplement_1):S167-S180. doi:10.2337/dc25-S008.
AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. Grunvald E, Shah R, Hernaez R, et al. Gastroenterology. 2022;163(5):1198-1225. doi:10.1053/j.gastro.2022.08.045.
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. Aronne LJ, Horn DB, le Roux CW, et al. The New England Journal of Medicine. 2025;. doi:10.1056/NEJMoa2416394.
Obesity Management in Adults: A Review. Elmaleh-Sachs A, Schwartz JL, Bramante CT, et al. JAMA. 2023;330(20):2000-2015. doi:10.1001/jama.2023.19897.
Semaglutide for Weight Loss and Cardiometabolic Risk Reduction in Overweight/Obesity. Mares AC, Chatterjee S, Mukherjee D. Current Opinion in Cardiology. 2022;37(4):350-355. doi:10.1097/HCO.0000000000000955.
Tirzepatide Once Weekly for the Treatment of Obesity. Jastreboff AM, Aronne LJ, Ahmad NN, et al. The New England Journal of Medicine. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038.